Choice of the anti-CD38 monoclonal antibody was supported by pre-clinical studies suggesting that CD38 is robustly expressed in T-ALL blasts thereby making it a potential effective target for daratumumab. The gene discussed is CD38; the disease is acute lymphoblastic leukemia.